Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0%

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 28,810,000 shares, a drop of 6.0% from the October 15th total of 30,640,000 shares. Based on an average trading volume of 1,830,000 shares, the days-to-cover ratio is currently 15.7 days.

Institutional Trading of Heron Therapeutics

Large investors have recently added to or reduced their stakes in the company. Congress Park Capital LLC grew its position in Heron Therapeutics by 25.3% during the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company's stock worth $3,936,000 after buying an additional 399,577 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Heron Therapeutics by 369.0% in the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company's stock valued at $1,273,000 after acquiring an additional 286,160 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Heron Therapeutics by 80.7% during the first quarter. BNP Paribas Financial Markets now owns 51,296 shares of the biotechnology company's stock worth $142,000 after acquiring an additional 22,904 shares during the period. Marshall Wace LLP increased its position in shares of Heron Therapeutics by 256.2% during the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company's stock valued at $6,164,000 after purchasing an additional 1,266,697 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Heron Therapeutics by 16.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 6,328 shares during the period. Institutional investors and hedge funds own 80.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HRTX. Needham & Company LLC lowered their target price on Heron Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. StockNews.com raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Wednesday, November 13th.

Heron Therapeutics Trading Down 1.7 %

HRTX traded down $0.02 during trading hours on Monday, hitting $1.17. The company's stock had a trading volume of 1,380,273 shares, compared to its average volume of 2,413,990. The company has a 50-day simple moving average of $1.82 and a 200 day simple moving average of $2.51. The firm has a market capitalization of $177.96 million, a PE ratio of -6.61 and a beta of 1.81. Heron Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The business had revenue of $32.81 million during the quarter, compared to the consensus estimate of $36.40 million. During the same quarter in the prior year, the company posted ($0.17) earnings per share. Research analysts expect that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.